Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,285,100
  • Shares Outstanding, K 57,472
  • Annual Sales, $ 51,500 K
  • Annual Income, $ -197,610 K
  • 60-Month Beta 2.20
  • Price/Sales 64.92
  • Price/Cash Flow N/A
  • Price/Book 3.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.73
  • Number of Estimates 8
  • High Estimate -1.62
  • Low Estimate -1.81
  • Prior Year -1.87
  • Growth Rate Est. (year over year) +7.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.41 +11.93%
on 06/03/19
61.95 -1.69%
on 06/11/19
-0.53 (-0.86%)
since 05/17/19
3-Month
54.41 +11.93%
on 06/03/19
74.50 -18.26%
on 04/05/19
-7.37 (-10.80%)
since 03/15/19
52-Week
37.44 +62.66%
on 12/24/18
90.98 -33.06%
on 09/25/18
-21.82 (-26.38%)
since 06/15/18

Most Recent Stories

More News
Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced it has promoted...

RARE : 60.90 (+6.54%)
Ultragenyx (RARE) Down 5.7% Since Last Earnings Report: Can It Rebound?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RARE : 60.90 (+6.54%)
Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp,...

RARE : 60.90 (+6.54%)
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -5.20% and -5.68%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

RARE : 60.90 (+6.54%)
Ultragenyx: 1Q Earnings Snapshot

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Monday reported a first-quarter loss of $96.8 million, after reporting a profit in the same period a year earlier.

RARE : 60.90 (+6.54%)
Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update

Strong Crysvita(R) (burosumab) Launch Continues with Approximately 730 Patients on Reimbursed Commercial Therapy in the United States

RARE : 60.90 (+6.54%)
What's in Store for Catalyst Pharma (CPRX) Q1 Earnings?

Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.

FOLD : 12.06 (+6.26%)
RARE : 60.90 (+6.54%)
ENDP : 3.91 (-3.46%)
CPRX : 3.80 (unch)
Factors Expected to Influence Qorvo (QRVO) in Q4 Earnings

Qorvo's (QRVO) expanding portfolio of 5G and GaN solutions hold promise.

AAPL : 193.89 (+0.60%)
SPNS : 16.16 (-1.10%)
RARE : 60.90 (+6.54%)
QRVO : 61.66 (+0.26%)
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?

Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.

RARE : 60.90 (+6.54%)
INO : 2.58 (+7.05%)
AMGN : 178.39 (+1.31%)
PLX : 0.42 (unch)
Ultragenyx to Host Conference Call for First Quarter 2019 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host...

RARE : 60.90 (+6.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade RARE with:

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Key Turning Points

2nd Resistance Point 63.15
1st Resistance Point 62.02
Last Price 60.90
1st Support Level 58.72
2nd Support Level 56.55

See More

52-Week High 90.98
Fibonacci 61.8% 70.53
Fibonacci 50% 64.21
Last Price 60.90
Fibonacci 38.2% 57.89
52-Week Low 37.44

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar